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Summary
Objective: We compared the efﬁcacy of etoricoxib 30 mg to placebo and ibuprofen 2400 mg for the treatment of osteoarthritis (OA) of the hip
and knee.
Design: In this 12-week, randomized, double-blind, placebo- and active-comparator-controlled trial, 548 patients (median age 63 years) with
OA of the hip or knee were randomized to receive placebo, etoricoxib 30 mg q.d., or ibuprofen 800 mg t.i.d. Demonstration of etoricoxib’s
efﬁcacy vs placebo and comparison of its efﬁcacy to ibuprofen were assessed using three co-primary endpoints: Western Ontario and
McMaster’s University Osteoarthritis Index (WOMAC) Pain Subscale (WOMAC-PS); WOMAC Physical Function Subscale (WOMAC-PFS);
and Patient Global Assessment of Disease Status (PGADS). Each primary endpoint utilizes a 0e100 mm visual analog scale. To demonstrate
comparable efﬁcacy of etoricoxib vs ibuprofen, the 95% conﬁdence intervals (CIs) for the difference in the least squares (LS) mean change
over 12 weeks for all three co-primary endpoints had to fall within 10 mm. Safety and tolerability data were collected throughout the study.
Results: Mean baseline values for the three co-primary endpoints ranged from 62.52 to 70.14 mm. Both etoricoxib and ibuprofen demon-
strated superior (P 0.002) efﬁcacy for all primary endpoints. The LS mean (mm) changes (95% CI) over 12 weeks for etoricoxib and
ibuprofen, respectively, compared to placebo were given as follows: WOMAC-PS: 11.66 (16.31, 7.01) and 7.62 (12.30, 2.94);
WOMAC-PFS: 10.15 (14.74, 5.57) and 7.23 (11.85, 2.61); PGADS: 11.65 (16.81, 6.50) and 8.11 (13.30, 2.92). The ef-
ﬁcacy of etoricoxib 30 mg was comparable to ibuprofen 2400 mg. All treatments were similarly well tolerated.
Conclusion: Treatment with etoricoxib 30 mg q.d. provides superior efﬁcacy vs placebo and comparable clinical efﬁcacy vs ibuprofen 2400 mg
(800 mg t.i.d.) for the treatment of OA of the hip and knee.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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of Disease Status, PGART Patient Global Assessment of Response to Therapy, q.d. once daily, t.i.d. three times daily, VA visual analog, VAS
visual analog scale, WOMAC Western Ontario and McMaster’s University Osteoarthritis Index, WOMAC-PS WOMAC Pain Subscale,
WOMAC-PFS WOMAC Physical Function Subscale.
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Osteoarthritis (OA), generally considered a disease of ag-
ing, is the most common form of arthritis in older adults.
In its severe form, the chronic pain of OA can lead to a sig-
niﬁcant reduction in the overall quality of life in patients of
any age1e4. OA of the knee and hip can be quite disabling
since these are major weight-bearing joints5. Given current
projections indicating that OA could be the fourth leading
cause of disability on a world-wide basis by the year
2020, the need for multiple treatment options exists6.8
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such as exercise and improvement of joint biomechanics,
are considered ﬁrst-line treatment options for patients with
OA7,8. However, traditional nonsteroidal anti-inﬂammatory
drugs (NSAIDs) are widely used to treat the pain and symp-
toms associated with this disease7,9,10. Nevertheless, there
is a greatly elevated risk of gastrointestinal (GI) toxicity
associated with traditional NSAIDs due to their additional
inhibition of the cyclooxygenase-1 (COX-1) isoenzyme.
This risk of NSAID-induced GI toxicity increases in a linear
fashion with age11.
Etoricoxib is a member of the COX-2 selective inhibitor
class of NSAIDs and exhibits a reduced risk of GI toxicity
compared to traditional NSAIDs12,13. Recent long-term
randomized placebo-controlled trials have demonstrated
an increased time-dependent risk of thrombotic cardio-
vascular (CV) events with other COX-2 selective NSAIDs
compared with placebo14,15. Meta-analyses and reviews
by regulatory authorities in the United States and Europe
indicate that this risk likely extends to traditional
NSAIDs16e19.
Etoricoxib’s anti-inﬂammatory and analgesic efﬁcacy for
the treatment of acute and chronic pain have been estab-
lished in multiple studies using a once daily dosing regimen
and is reviewed elsewhere20. In countries where it is ap-
proved, the recommended once daily dose of etoricoxib
for the treatment of OA is 60 mg. The purpose of this study,
the second of two replicate, randomized, placebo- and ac-
tive-comparator-controlled trials, was to examine the efﬁ-
cacy as well as the safety and tolerability of etoricoxib
30 mg q.d. compared to placebo and ibuprofen 800 mg
t.i.d. in patients with OA of the knee or hip. In the ﬁrst of
these two studies (Sponsor protocol number 071), the efﬁ-
cacy of etoricoxib 30 mg was found to be superior to pla-
cebo and comparable to ibuprofen 2400 mg for the
treatment of OA of the hip and knee21. The identiﬁcation
of lower effective doses of NSAIDs including selective
COX-2 inhibitors is important in the context of mechanism-
based side effects such as edema and hypertension, which
are known to be dose-related.
Patients and methods
The protocol for this study was approved by the Institu-
tional Review Board at each study center. All patients pro-
vided written informed consent prior to their participation
in the study.
This 12-week, placebo- and active-comparator-controlled
trial was conducted in 548 patients in 49 centers (41 in the
United States and eight in Latin America) under double-
blind (with in-house blinding) conditions to evaluate the efﬁ-
cacy, safety, and tolerability of etoricoxib 30 mg compared
to placebo and ibuprofen 800 mg t.i.d. for the treatment of
OA of the knee and hip. Otherwise healthy male and female
OA patients 40 years or older, were enrolled. Women of
child-bearing potential were determined to be in a nongravid
state and were instructed to use contraceptive measures
during the study. Eligible patients were required to have
a clinical and radiographic diagnosis of OA of the knee or
hip for at least the previous 6 months or were newly diag-
nosed patients with clinical symptoms consistent with OA
of the study joint for at least the previous 6 months. All pa-
tients were required to have pain on motion or weight bear-
ing for the majority of days during the previous month, which
was partially relieved by rest. Radiographic criteria included
joint space narrowing for hip OA. Patients with knee OAwere required to have both tibiofemoral osteophytes and ti-
biofemoral joint space narrowing. All eligible patients met
American Rheumatism Association (ARA) functional class
I, II, or III criteria22 and were required to have been using
NSAIDs or acetaminophen to treat their OA. The primary
source of pain for each patient was in the lower extremity.
In cases where both knees and/or hips were affected, the
most painful joint was selected for study evaluation.
Patients who were regular users of NSAIDs (at least 25 of
the last 30 days preceding enrollment) were required to
have a prestudy score of less than 80 mm (based on the
0e100 mm visual analog scale [VAS]) for patient assess-
ment of pain while walking on a ﬂat surface. Following ces-
sation of NSAID therapy (washout period) patients were
instructed to return to the clinic upon experiencing a ﬂare
of OA pain. Prespeciﬁed washout periods for the various
prior NSAIDs that were used ranged from 3 to 20 days.
A sufﬁcient ﬂare within the washout period was deﬁned as
a patient-reported pain score of at least 40 mm while the pa-
tient walked on a ﬂat surface, and was at least 15 mm
greater than that recorded at the prestudy visit as well as
a worsening of at least one point (0- to 5-point Likert scale)
for Investigator Global Assessment of Disease Status
(IGADS).
Patients who were classiﬁed as acetaminophen users
(1.2e4 g of acetaminophen daily for at least 25 of the last
30 days preceding enrollment) reported no NSAID use for
treatment of their OA and were required to have minimum
scores of 40 mm for patient-reported pain while walking
on a ﬂat surface and Patient Global Assessment of Disease
Status (PGADS), and an IGADS of fair, poor, or very poor.
The number of acetaminophen users at each study site was
limited to 20%, since this agent acts only as an analgesic,
and unlike etoricoxib and ibuprofen, does not have anti-
inﬂammatory activity.
All patients were required to stop taking rescue acetamin-
ophen at least 12 h (24 h if they were using extended-
release formulations) prior to all treatment visits and for
acetaminophen users only, prior to screening.
EXCLUSION CRITERIA
Patients were excluded if they had medical conditions,
such as recent joint injuries or rheumatologic, autoimmune,
or musculoskeletal diseases that could confound or inter-
fere with efﬁcacy evaluations.
TREATMENT
Qualiﬁed patients were randomized to receive placebo,
etoricoxib 30 mg q.d., or ibuprofen 800 mg t.i.d. for 12
weeks. Within each study center, patients were randomly
allocated using a computer-generated allocation schedule;
allocation was not stratiﬁed in this study. All study person-
nel, including investigators, study site personnel, patients,
monitors, central laboratory and other study personnel, re-
mained blinded to treatment allocation throughout the
study. Study medication was supplied in two coded study
bottles, labeled ‘‘bottle A’’ (containing either etoricoxib
30 mg tablets or matching placebo) and ‘‘bottle B’’ (contain-
ing either ibuprofen 800 mg tablets or matching placebo).
Patients were instructed to take one tablet in the morning
from bottle A and one tablet in the morning, afternoon,
and evening from bottle B. Acetaminophen was provided
as rescue medication for pain, if needed. Treatment compli-
ance and amount of rescue acetaminophen use were deter-
mined by tablet counts.
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Patients were allowed to continue use of chronic medica-
tions provided they remained on stable doses 2 weeks be-
fore and throughout the 12 weeks of the study. The use of
intra-articular corticosteroids or hyaluronic acid injections to
the study knee within the previous 3 months, use of immu-
nosuppressants within the previous 3 months, corticoste-
roid use by any systemic route, and hyaluronic acid
injections or intra-articular corticosteroids for any other joint
in the previous month were not permitted. Patients taking
stable doses of glucosamine or chondroitin sulfate for at
least 6 months prior to the study were allowed to enroll.
Low-dose aspirin (100 mg daily) use for cardioprophylaxis
was permitted; however, patients were excluded if they
were required to take any other therapy to inhibit platelet ag-
gregation. Gastroprotective agents (GPAs), such as proton
pump inhibitors, H2-receptor antagonists, sucralfate, and
misoprostol, were allowed as necessary.
EFFICACY ASSESSMENTS
Efﬁcacy was evaluated at 2, 4, 8, and 12 weeks following
initiation of therapy. Primary endpoints included the West-
ern Ontario and McMaster’s University Osteoarthritis Index
(WOMAC) visual analog (VA) 3.0 pain (WOMAC-PS) and
physical function (WOMAC-PFS) subscales and the
PGADS (0e100 mm VAS)23e25. Secondary and other end-
points included the Patient Global Assessment of Re-
sponse to Therapy (PGART; 0e4 point Likert scale), the
IGADS (0e4 point Likert scale), the WOMAC stiffness sub-
scale (0e100 mm VAS), the WOMAC questionnaire overall
score and subscale averages, the Investigator Global As-
sessment of Response to Therapy (IGART; 0e4 point Likert
scale), joint tenderness (0e3 point Likert scale), the propor-
tion of patients discontinuing due to lack of efﬁcacy, rescue
acetaminophen use, and the WOMAC pain while walking
on a ﬂat surface questionnaire (0e100 mm VAS). Explor-
atory endpoints included the WOMAC nighttime pain and
WOMAC 3.0 stiffness upon ﬁrst awakening subscales
(0e100 mm VAS).
SAFETY AND TOLERABILITY ASSESSMENTS
Adverse experiences (AEs) were recorded throughout
the study and for 14 days after the last dose of study
drug. Physical examinations, clinical laboratory tests, and
AEs were recorded throughout the study to assess safety.
Serious AEs were deﬁned as those events that resulted
in death, were life threatening, resulted in or prolonged
hospitalization, or caused persistent or signiﬁcant disabil-
ity or incapacity. AEs that were determined by the inves-
tigator to be possibly, probably, or deﬁnitely drug-related
were classiﬁed as drug-related. Prespeciﬁed safety-re-
lated endpoints, including the proportion of patients with
edema-related AEs; hypertension-related AEs; AEs of
congestive heart failure (CHF), pulmonary edema, or car-
diac failure; and discontinuation due to digestive system
or abdominal pain AEs, edema-related AEs, or hyperten-
sion-related AEs were also recorded to more closely
examine GI safety and possible clinical sequelae of mod-
ulating renal prostaglandin biosynthesis. Prior to initiation
of the study, blinded, external adjudication committees
were established to evaluate any investigator-reported
thrombotic cardiovascular serious AEs (thrombotic CV
events) or potential upper GI perforations, ulcers, or
bleeds that occurred during the trial.STATISTICAL ANALYSIS
For power calculations, the estimates for variability and
assumed mean changes for each treatment group were
based on results from three previous etoricoxib and two pre-
vious rofecoxib randomized, placebo-controlled studies in
patients with OA26e30. Results from these studies sug-
gested that the expected differences between responses
to etoricoxib relative to placebo were approximately
11.9 mm for the WOMAC-PS, 10.0 mm for the WOMAC-
PFS, and 13.5 mm for the PGADS. Using variability esti-
mates from the two etoricoxib Phase III studies27,28, it was
predicted that planned sample sizes of 100 placebo pa-
tients and 200 etoricoxib 30 mg patients provided >97%
power to detect (a¼ 0.050, two-sided) these expected
mean differences for the three co-primary endpoints. The
modiﬁed intention-to-treat (MITT) population was used in
all efﬁcacy analyses and is deﬁned as all randomized pa-
tients who received at least one dose of study medication
and who provided a baseline and at least one post-baseline
observation.
The time-weighted mean changes from baseline for each
efﬁcacy endpoint were analyzed using an analysis of co-
variance (ANCOVA) model with treatment and primary OA
study joint as the main effects and the baseline value as
the covariate. For endpoints without a relevant baseline
measurement, the on-treatment response was analyzed us-
ing analysis of variance (ANOVA).
The between-treatment comparisons of interest were
divided into three families of tests, using the Dunnette
Tamhane approach31; (1) testing of the efﬁcacy of etori-
coxib relative to placebo, (2) comparing the relative efﬁcacy
of etoricoxib 30 mg to ibuprofen 2400 mg, and (3) evaluat-
ing the study sensitivity, i.e., comparing ibuprofen to pla-
cebo. The different between-treatment comparisons in
each family addressed related yet different questions. In ad-
dition, there was only one test within each family; therefore,
no adjustment for multiple between-treatment comparisons
was made between these three families of tests. Since the
primary hypothesis had to be satisﬁed for each of the three
primary endpoints, the overall alpha level was <0.050 and
no adjustment was necessary. For comparisons to placebo,
all three primary endpoints were required to reach statistical
signiﬁcance at a¼ 0.050, two-tailed.
Statistical tests and estimators of the secondary end-
points and other secondary statistical analyses were sup-
portive and helped in interpreting the primary analyses,
establishing efﬁcacy proﬁles, and checking the consistency
of ﬁndings for the primary endpoints. Therefore, no multiple
testing adjustments were made. All tests for difference in
means were made at the customary two-sided a¼ 0.050
level.
To demonstrate comparable efﬁcacy of etoricoxib 30 mg
q.d. and ibuprofen 800 mg t.i.d., the 95% conﬁdence inter-
vals (CIs) for the mean differences in the time-weighted av-
erage response between the two groups had to fall entirely
within 10 mm on a 100 mm VAS for all three co-primary
endpoints. The study was designed to provide greater
than 95% power to yield all three CIs within 10 mm if
true differences in efﬁcacy between etoricoxib 30 mg and
ibuprofen 2400 mg were zero.
The incidences of prespeciﬁed clinical AEs and labora-
tory AEs of interest in the two active treatment groups
were individually compared with the incidence in the pla-
cebo group using Fisher’s exact test. Differences between
treatment groups in proportions of patients with AEs or
those exceeding predeﬁned limits of change in laboratory
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Results
PATIENTS
A total of 548 of the 861 patients screened met the el-
igibility criteria and were randomized (Fig. 1). Baseline
patient characteristics were similar among the treatment
groups (Table I). The majority of enrolled patients were
female. The median age of the study population was 63
years, and the majority of patients (56%) were over 60
years and 22% were over 70 years. The mean duration
of OA was 6.6 years, and the majority of patients were
ARA functional class II. There were small insigniﬁcant dif-
ferences among treatment groups in the proportions of
patients who were classiﬁed as ARA functional class I,
II, and III. Given the overlap between the diagnostic entry
criteria used and those of the American College of Rheu-
matology (ACR) clinical and radiographic diagnostic crite-
ria, all patients with hip OA and all patients >50 years of
age with knee OA also met ACR diagnostic criteria32. Al-
though it is likely that knee OA patients <50 years of age
also met ACR criteria, this was not speciﬁcally docu-
mented as we did not speciﬁcally require patients to
have one of the two ACR criteria of crepitus or stiffness
<30 min. Of note, 88% of patients enrolled were >50
years of age.Most patients (83%) had OA of the knee and 89% were
NSAID users at screening. A small percentage of patients
(4.2%) had a prior medical history of conﬁrmed gastric or
duodenal ulcer or upper GI bleeding. Baseline characteris-
tics (e.g., percentage of patients with OA of the knee, ARA
functional class, and mean duration of disease) for the
patients in this study were similar to those in other studies
of etoricoxib in patients with OA26e28. The most common
secondary diagnosis at baseline was hypertension (46.4%
of the patients). A total of four, seven, and four patients in
the placebo, etoricoxib, and ibuprofen groups, respectively,
were excluded from the MITT analysis for any of the three
co-primary efﬁcacy endpoints.
EFFICACY
Mean values for all efﬁcacy endpoints were qualitatively
similar among the treatment groups at baseline (Table II).
Near-maximal efﬁcacy was achieved with both active treat-
ments by the ﬁrst visit following initiation of treatments
(week 2), followed by slight continued improvement for all
primary endpoints through 12 weeks [Fig. 2(a)e(c)]. There
were no signiﬁcant treatment-by-baseline-covariate (i.e.,
age group [<65 years, 65 years], gender, racial back-
ground, ARA functional class, or duration of OA) or treat-
ment-by-study-joint interactions observed. Results of the
treatment comparisons of the last observed value were con-
sistent with those of the time-weighted average responses
over the 12-week treatment period.Fig. 1. Disposition of patients with OA enrolled in 12-week evaluation of etoricoxib 30 mg and ibuprofen 2400 mg vs placebo. y: The most
common reasons patients were not randomized were due to failure to meet one or more inclusion criteria (i.e., not satisfying ﬂare criteria
and having a clinical diagnosis of OA based on clinical and radiographic criteria) or because one or more exclusion criteria were met (i.e.,
having an abnormal laboratory safety test result). z: Other reasons for discontinuation included lost to follow-up; unknown reason; patient
moved; patient withdrew consent; and protocol deviation.
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were signiﬁcantly more effective (P 0.002) than placebo
[Fig. 2(d) and Table II]. Etoricoxib met the predeﬁned criteria
for comparability to ibuprofen for all co-primary endpoints;
additionally, etoricoxib demonstrated statistical superiority
(P< 0.05) over ibuprofen for the WOMAC-PS, a co-primary
endpoint. Analyses of key secondary endpoints, which in-
cluded PGART, IGADS, WOMAC stiffness subscale, and
WOMAC overall score and subscale averages, provided an
additional perspective of etoricoxib’s overall efﬁcacy proﬁle
for the treatment of OA compared with the efﬁcacy of ibupro-
fen and placebo. Etoricoxib and ibuprofen demonstrated
comparable treatment effects, which were superior to pla-
cebo (Table II) for these secondary endpoints. These treat-
ment effects were consistent with those of the co-primary
endpoints.
From an exploratory post hoc analysis it was determined
that 80.0%, 70.1%, and 55.1% of patients in the etoricoxib,
ibuprofen, and placebo group, respectively, achieved what
can be considered to be a minimally clinically important im-
provement33 (15% improvement from baseline) for the
WOMAC-PS. Similar response rates of 72.6%, 66.5%,
and 53.2% for WOMAC-PFS and 77.7%, 73.9%, and
61.7% for PGADS for etoricoxib, ibuprofen, and placebo, re-
spectively, were observed.
Results for other secondary and exploratory endpoints
were also consistent with results for the co-primary end-
points. Patients on etoricoxib experienced a 1.54 point
(95% CI: 1.40, 1.68) improvement of IGART and
33.75 mm (95% CI: 37.17, 30.33 mm) improvement
Table I
Baseline characteristics for patients enrolled in clinical study of
etoricoxib and ibuprofen for treatment of OA
Characteristic Placebo
(n¼ 111)
Etoricoxib
30 mg
(n¼ 224)
Ibuprofen
2400 mg
(n¼ 213)
Gender, n (%)
Female 84 (75.7) 174 (77.7) 157 (73.7)
Male 27 (24.3) 50 (22.3) 56 (26.3)
Race, n (%)
Asian 2 (1.8) 4 (1.8) 4 (1.9)
Black 5 (4.5) 10 (4.5) 3 (1.4)
Hispanic American 27 (24.3) 47 (21.0) 50 (23.5)
Multiracial 26 (23.4) 53 (23.7) 52 (24.4)
White 51 (45.9) 110 (49.1) 104 (48.8)
Age (years)
Mean [standard
deviation (SD)]
64.0 (10.1) 62.1 (9.0) 62.3 (9.6)
Median 65.0 62.0 62.0
Range 43e85 42e81 41e86
Primary OA joint, n (%)
Knee 91 (82.0) 189 (84.4) 176 (82.6)
Hip 20 (18.0) 35 (15.6) 37 (17.4)
Mean duration of OA,
years (SD)
6.5 (6.6) 6.6 (7.3) 6.7 (8.0)
ARA functional class, n (%)
Class I 25 (22.7) 68 (30.4) 54 (25.4)
Class II 69 (62.7) 128 (57.1) 126 (59.2)
Class III 16 (14.5) 28 (12.5) 33 (15.5)
Mean height, cm (SD) 161.0 (11.2) 160.6 (12.1) 161.6 (11.8)
Mean weight, kg (SD) 80.1 (17.3) 81.9 (20.9) 79.2 (18.6)
Low-dose
(100 mg/day)
aspirin use, n (%)
22 (19.8) 38 (17.0) 36 (16.9)of pain status when walking on a ﬂat surface (WOMAC
score). This was similar to the improvements observed in
patients taking ibuprofen (1.58 [95% CI: 1.44, 1.73] and
32.01 [95% CI: 35.44, 28.57] for IGART and pain sta-
tus when walking on a ﬂat surface, respectively). When
compared with placebo, treatment with etoricoxib provided
signiﬁcant reduction of study joint tenderness (P¼ 0.005),
whereas reduction of study joint tenderness following ibu-
profen therapy only approached signiﬁcance (P¼ 0.076).
Both etoricoxib and ibuprofen signiﬁcantly reduced night
pain and stiffness upon awakening vs placebo
(P 0.016). Although the treatment effects for etoricoxib
and ibuprofen were similar for stiffness upon awakening,
the effect of etoricoxib on night pain was signiﬁcantly
greater than ibuprofen (P¼ 0.041).
Patients treated with etoricoxib or ibuprofen used signiﬁ-
cantly less acetaminophen than those receiving placebo
(P¼ 0.003 for etoricoxib and P¼ 0.029 for ibuprofen) for
the treatment of breakthrough pain. The amount of rescue
acetaminophen use in the etoricoxib and ibuprofen groups
was similar.
SAFETY AND TOLERABILITY
The incidences of 10 prespeciﬁed AEs were compared
among the treatment groups (Table III). Etoricoxib and ibu-
profen at the doses used in this study were generally safe
and well tolerated. The percentage of patients experienc-
ing an AE or a serious AE was similar among the three
groups (Table III). The incidence of drug-related AEs in
patients receiving ibuprofen was signiﬁcantly greater than
for patients treated with placebo (P¼ 0.029). The percent-
age of patients who discontinued due to any AE was
higher in the ibuprofen group than in the placebo and etor-
icoxib groups but the difference was not signiﬁcant. Only
one serious AE (in the ibuprofen group) was considered
drug-related.
The most common drug-related AEs were epigastric dis-
comfort, nausea, dyspepsia, and hypertension. Drug-
related epigastric discomfort occurred most frequently in
the ibuprofen group (9.4% vs 2.7% of those treated with
etoricoxib and 1.8% of the placebo group; Table III) with
95% CIs for the difference between etoricoxib and ibupro-
fen as well as between ibuprofen and placebo that did not
cross zero, consistent with the higher incidence for ibupro-
fen. Drug-related nausea occurred most frequently in the
ibuprofen group, whereas dyspepsia was reported with
similar frequency across all groups. Discontinuations due
to AEs related to the digestive system or abdominal pain
were similar in the placebo and ibuprofen groups and
were slightly lower in the etoricoxib group. One patient in
this study had a conﬁrmed upper GI event. This patient,
who was in the ibuprofen group, had a conﬁrmed gastric
ulcer that was deemed complicated due to hemorrhage.
The investigator determined that this AE was probably
drug-related.
The incidence of edema-related AEs was similar for etor-
icoxib and ibuprofen and was the lowest for placebo al-
though this difference was not signiﬁcant (Table III). The
incidence of hypertension-related AEs was signiﬁcantly
higher in the etoricoxib (6.3%; P< 0.05) and ibuprofen
(8.9%; P< 0.005) groups compared with placebo (0.9%;
Table III). However, the rate of discontinuation due to hyper-
tension-related AEs was low and similar among the groups.
One patient each in the etoricoxib and ibuprofen groups ex-
perienced CHF.
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Summary of results for primary and key secondary efficacy endpoints over the 12-week treatment period
Baseline
mean
LS mean (95% CI)
change from baseliney
Difference from placebo
in LS mean change (95% CI)y
Difference from ibuprofen in
LS mean change (95% CI)y
Primary endpoints
WOMAC-PS (0e100 VAS)
Placebo (n¼ 109) 64.66 16.47 (20.55, 12.40) N/A N/A
Etoricoxib 30 mg (n¼ 220) 66.46 28.14 (31.23, 25.04) 11.66 (16.31, 7.01) 4.04 (7.86, 0.21)
Ibuprofen 2400 mg (n¼ 211) 64.74 24.10 (27.20, 20.99) 7.62 (12.30, 2.94) N/A
WOMAC-PFS (0e100 VAS)
Placebo (n¼ 109) 64.23 13.56 (17.59, 9.54) N/A N/A
Etoricoxib 30 mg (n¼ 219) 64.27 23.46 (26.78, 20.65) 10.15 (14.74, 5.57) 2.92 (6.71, 0.87)
Ibuprofen 2400 mg (n¼ 209) 62.52 20.09 (23.87, 17.72) 7.23 (11.85, 2.61) N/A
PGADS (0e100 VAS)
Placebo (n¼ 107) 66.93 17.85 (22.41, 13.29) N/A N/A
Etoricoxib 30 mg (n¼ 220) 70.14 29.50 (32.91, 26.10) 11.65 (16.81, 6.50) 3.54 (7.75, 0.67)
Ibuprofen 2400 mg (n¼ 211) 69.88 25.97 (29.39, 22.54) 8.11 (13.30, 2.92) N/A
Key secondary endpoints
PGART (0e4 Likert scale)
Placebo (n¼ 108) e 2.29 (2.09, 2.49) N/A N/A
Etoricoxib 30 mg (n¼ 220) e 1.61 (1.46, 1.76) 0.68 (0.91, 0.45) 0.11 (0.30, 0.08)
Ibuprofen 2400 mg (n¼ 210) e 1.72 (1.57, 1.87) 0.57 (0.80, 0.34) N/A
IGADS (0e4 Likert scale)
Placebo (n¼ 109) 2.83 1.00 (1.15, 0.84) N/A N/A
Etoricoxib 30 mg (n¼ 220) 2.85 1.37 (1.48, 1.25) 0.37 (0.54, 0.19) 0.09 (0.23, 0.06)
Ibuprofen 2400 mg (n¼ 211) 2.88 1.28 (1.40, 1.16) 0.28 (0.46, 0.10) N/A
WOMAC stiffness subscale (0e100 VAS)
Placebo (n¼ 109) 67.06 16.26 (20.61, 11.91) N/A N/A
Etoricoxib 30 mg (n¼ 218) 65.68 24.60 (27.92, 21.28) 8.34 (13.30, 3.38) 1.68 (5.77, 2.41)
Ibuprofen 2400 mg (n¼ 209) 65.32 22.92 (26.24, 19.60) 6.66 (11.66, 1.67) N/A
WOMAC questionnaire overall score average (0e100 VAS)
Placebo (n¼ 109) 64.56 14.43 (18.39, 10.48) N/A N/A
Etoricoxib 30 mg (n¼ 218) 64.95 24.90 (27.92, 21.87) 10.46 (14.97, 5.95) 3.17 (6.89, 0.56)
Ibuprofen 2400 mg (n¼ 209) 63.18 21.73 (24.75, 18.71) 7.29 (11.84, 2.75) N/A
WOMAC questionnaire overall subscale average (0e100 VAS)
Placebo (n¼ 109) 65.32 15.53 (19.50, 11.55) N/A N/A
Etoricoxib 30 mg (n¼ 218) 65.49 25.64 (28.67, 22.60) 10.11 (14.64, 5.58) 2.90 (6.64, 0.84)
Ibuprofen 2400 mg (n¼ 209) 64.13 22.74 (25.77, 19.70) 7.21 (11.77, 2.64) N/A
Number of patients in the MITT analysis. yLower values indicate a greater treatment effect. Where there is no baseline value, the mean
on-treatment response is given.There were a total of ﬁve investigator-reported thrombotic
CV events (all nonfatal); one deep vein thrombosis (DVT)
for placebo, two cerebrovascular accidents (CVAs) for etor-
icoxib, and an embolic stroke and DVT for ibuprofen. Of
these events, three were conﬁrmed thrombotic CV events;
the DVT on placebo, one CVA on etoricoxib, and one em-
bolic stroke on ibuprofen. None of these three thrombotic
CV events was considered to be drug-related by the
investigators.
Laboratory AEs were generally more frequent in the
ibuprofen group than for placebo or etoricoxib. Overall
laboratory AEs occurred in four (3.7%) patients treated
with placebo, seven (3.2%) treated with etoricoxib, and
18 (8.5%) treated with ibuprofen. Drug-related laboratory
AEs occurred in 1.9% of the placebo-treated patients,
2.3% of those treated with etoricoxib, and 7.1% of the pa-
tients treated with ibuprofen. The most common labora-
tory AE considered drug-related by investigators was
increased alanine aminotransferase (ALT), the incidence
of which was higher in the ibuprofen group (2.4%) than
the placebo (0.9%) and etoricoxib (0%) groups. The
next most common drug-related laboratory AEs were in-
creased blood urea nitrogen and serum creatinine withthe highest incidence in the ibuprofen group (both
1.9%), with both of these AEs occurring in 0.5% of pa-
tients in the etoricoxib group, and in no patients in the
placebo group.
The 95% CIs for the difference between the etoricoxib
and ibuprofen groups for overall laboratory AEs (95% CI:
10.2, 0.9) and drug-related laboratory AEs (95% CI:
9.3, 0.8) did not cross zero which is consistent with
a higher incidence on ibuprofen. Discontinuations due to
laboratory AEs occurred in two patients in the placebo
and two patients in the ibuprofen groups. The increased in-
cidence of laboratory AEs in the ibuprofen group was
mainly due to increases of ALT, blood urea nitrogen, and
serum creatinine. Decreases in hemoglobin values were
rare and occurred in 0.9%, 0.0%, and 1.9% of patients in
the placebo, etoricoxib, and ibuprofen groups, respectively.
Discussion
This study used validated clinical endpoints for the as-
sessment of treatment efﬁcacy in patients with OA34,35.
The demographic characteristics of the patient population
1354 A. Puopolo et al.: Comparing the efﬁcacy of etoricoxib and ibuprofen for the treatment of patients with OAFig. 2. Co-primary endpoints evaluated (0e100 mm VAS) over 12-week period of treatment with placebo, etoricoxib 30 mg/day, or ibuprofen
2400 mg/day in patients with OA of the knee or hip. (a) WOMAC-PS; (b) WOMAC-PFS; (c) PGADS; and (d) pairwise treatment differences
(VAS) in co-primary endpoints for patients with OA treated daily with etoricoxib 30 mg, ibuprofen 2400 mg, or placebo. Note: the week number
for each group has been shifted along the horizontal scale to improve legibility. Error bars are standard errors. S ¼ screening and
R¼ randomization.at baseline were similar to those of OA patients in the gen-
eral population that seek treatment5,7. Consistent with other
clinical studies, the results of this trial conﬁrm the superior
clinical efﬁcacy of etoricoxib 30 mg q.d. compared with pla-
cebo21,26 and its comparable efﬁcacy to ibuprofen 2400 mg
daily21. Improvement of all co-primary endpoints for etori-
coxib and ibuprofen was evident within 2 weeks of the initial
dose of study medication and was maintained throughout
the 12 weeks of active therapy.
It is important in trials of this nature to determine
whether the magnitude of the observed changes com-
pared to placebo for indices of pain and physical function
is actually clinically meaningful. In this and a similar
study21, the magnitude of the treatment responses for
WOMAC subscales of pain and physical function in the
etoricoxib group was in the range of changes recognized
to be clinically meaningful to patients with OA of the knee
or hip36. The signiﬁcant efﬁcacy of etoricoxib 30 mg vs
placebo across the range of efﬁcacy domains, including
pain, stiffness, and physical function, clearly demon-
strates its overall clinical effectiveness for the treatment
of OA. Relief of morning stiffness for patients taking etor-
icoxib 30 mg is indicative of its sustained efﬁcacy over
the 24-h dosing interval and consistent with its pharmaco-
kinetic proﬁle37.
Etoricoxib 30 mg and ibuprofen 2400 mg were both gen-
erally well tolerated in this study. The concomitant use of
GPAs in this study does not allow for a rigorous comparison
of GI safety and tolerability between treatments. However,
the numerically lower incidence of GI AEs, despite the
use of GPAs, is consistent with previous comparisons ofGI safety and tolerability of etoricoxib to traditional
NSAIDs12,13,38,39.
The occurrence of renovascular AEs was closely moni-
tored in this study because the role of prostaglandins in
the regulation of renal homeostasis is well recognized40.
Data from the third National Health and Nutrition Examina-
tion Survey indicate that approximately 40% of adults with
OA also have hypertension, which is similar to the baseline
status of the population in the present study41. In this study,
the incidence of hypertension-related AEs was signiﬁcantly
higher for patients taking either ibuprofen or etoricoxib com-
pared with placebo, with the highest incidence occurring in
patients on ibuprofen. The incidence of edema-related AEs
was similar in patients treated with etoricoxib 30 mg and
ibuprofen 2400 mg and was numerically higher in patients
receiving either active treatment compared with placebo.
These data point out the importance of monitoring blood
pressure in all patients on NSAID therapy.
This clinical trial was not designed to assess the throm-
botic CV safety of etoricoxib or ibuprofen relative to pla-
cebo. However, a large, long-term non-inferiority clinical
trials program, the Multinational Etoricoxib and Diclofenac
Arthritis Long-term (MEDAL) Program42,43, designed to as-
sess the thrombotic CV risk of etoricoxib (60 or 90 mg) rel-
ative to the traditional NSAID diclofenac 150 mg in OA and
rheumatoid arthritis patients, has recently been completed.
The MEDAL Program demonstrated that rates of conﬁrmed
thrombotic CV events were comparable, yielding a hazard
ratio of 0.95 (95% CI: 0.81, 1.11)43. These data help to in-
form the beneﬁts and risks of treatment with a selective
COX-2 inhibitor such as etoricoxib.
1355Osteoarthritis and Cartilage Vol. 15, No. 12Conclusion
In this trial, treatment with etoricoxib 30 mg q.d. for the
treatment of OA is well tolerated and provides therapeutic
effectiveness that is superior to placebo and comparable
to ibuprofen 2400 mg (800 mg t.i.d).
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